CoChat

Phaeohyphomycosis in a Tertiary Care Cancer Center

Open access
Ben‐Ami, Ronen, Lewis, Russell E., Raad, Issam I., Kontoyiannis, Dimitrios P. · 2009 · Clinical Infectious Diseases
Cited by 131

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Phaeohyphomycosis is a rare opportunistic fungal infection. To assess the range of clinical presentations and outcomes of phaeohyphomycosis in patients with cancer, we reviewed cases diagnosed at the M. D. Anderson Cancer Center (Houston, TX). METHODS: We searched the microbiology laboratory records for dematiaceous molds that had been isolated during the period from January 1989 through March 2008. Demographic and clinical data were abstracted from patients' medical records. Invasive phaeohyphomycosis was defined according to the criteria of the European Organization for Research and Treatment of Cancer Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycosis Study Group for proven or probable invasive fungal disease. Archived dematiaceous mold isolates were tested for antifungal drug susceptibility. RESULTS: Of 348 isolates of dematiaceous fungi recovered, only 39 isolates (11%), recovered from 39 patients, were associated with proven or probable invasive fungal disease (33 proven and 6 probable). The incidence rate of phaeohyphomycosis increased from 1.0 to 3.1 cases per 100,000 patient-days during the study period (P = .006). Of these 39 patients, 14 (36%) had a breakthrough infection while receiving prophylactic or empirical antifungal therapy. Sites of infection were the lungs (15 [38%] of 39 patients), skin (15 [38%]), sinuses (14 [36%]), and bloodstream (7 [18%]). Thirteen patients (33%) had a disseminated infection. Values of the serum galactomannan index were measured for 11 (28%) of 39 patients. The galactomannan index value was elevated (>0.5) in 5 (45%) of these 11 patients. The mortality rate at 12 weeks was 33%. Cox regression analysis revealed a significantly higher risk of death for patients with disseminated infection (hazard ratio, 5.7; P = .03) and a lower risk for patients who recovered from neutropenia within 30 days (hazard ratio, 0.2; P = .04). Isolates were frequently not susceptible to voriconazole and caspofungin. CONCLUSIONS: Although rare, dematiaceous molds are increasingly encountered in immunosuppressed patients with cancer. The propensity of these fungi for dissemination and for resistance to antifungal drugs presents management challenges.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1086/597400

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 131

Metadata

Authors
Ben‐Ami, R., Lewis, R. E., Raad, I. I., & Kontoyiannis, D. P.
Venue
Clinical Infectious Diseases
Published
2009-04-15
Volume
48
Issue
8
Pages
1033-1041
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2154300911
Cited by
131
References
3
FWCI
6.99
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phaeohyphomycosis in a Tertiary Care Cancer Center. https://app.cochat.ai/papers/10.1086/597400
The paper
Ben‐Ami, R., Lewis, R. E., Raad, I. I., & Kontoyiannis, D. P. (2009). Phaeohyphomycosis in a Tertiary Care Cancer Center. Clinical Infectious Diseases. https://doi.org/10.1086/597400

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.